Guidance on treatment endpoints and study design for clinical trials aiming to achieve cure in chronic hepatitis B and D: Report from the 2022 AASLD-EASL HBV/HDV treatment endpoints conference

Representatives from academia, industry, regulatory agencies, and patient advocacy groups convened under AASLD and EASL in June 2022 with the primary goal of achieving consensus on chronic hepatitis B virus (HBV) and hepatitis delta virus (HDV) (HDV) treatment endpoints to guide clinical trials aimi...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of hepatology 2023-11, Vol.79 (5), p.1254-1269
Hauptverfasser:	Ghany, Marc G., Buti, Maria, Lampertico, Pietro, Lee, Hannah M., Berg, Thomas, Brunetto, Maurizia R., Buchholz, Stephanie, Chang, Kyong-Mi, Chen, Jacki, Cornberg, Markus, Dandri, Maura, Dusheiko, Geoffrey, Easterbrook, Philippa, Feld, Jordan J., Ghany, Marc, Janssen, Harry L.A., Korenjak, Marko, Lee, Hannah, Liang, Jake, Lok, Anna S., Negro, Francesco, Rehermann, Barbara, Sheikh, Virginia, Papatheodoridis, George, Petersen, Jӧrg, Terrault, Norah, Younossi, Zobair M., Yuen, Man-Fung
Format:	Artikel
Sprache:	eng
Schlagworte:	Antiviral Agents - therapeutic use Biomarkers Cirrhosis Clinical Outcomes Clinical Trials as Topic - methods Clinical Trials, Phase II as Topic - methods Cure DNA, Viral - analysis DNA, Viral - blood Endpoint Determination - methods Hepatitis B Surface Antigens - blood Hepatitis B virus - genetics Hepatitis B, Chronic - drug therapy Hepatitis B, Chronic - therapy Hepatitis B, Chronic - virology Hepatitis D, Chronic - drug therapy Hepatitis Delta Virus - genetics Humans Novel therapy Research Design Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!